AstraZeneca has offered to reduce drug prices in the United States after pressure from President Donald Trump’s administration. The proposal comes as Trump pushes pharmaceutical companies to align U.S. prices with those in other countries.

The pharmaceutical company also committed to investing $50 billion in the U.S., which includes a new manufacturing site in Virginia and expansions in Maryland, Texas, Massachusetts, California, and Indiana. The move is part of a broader strategy to increase U.S.-based production, particularly for cholesterol and weight-loss treatments.

AstraZeneca CEO Pascal Soriot said the company would propose modest price increases in other countries to offset the U.S. reductions. He added that the goal is to rebalance the pricing model globally.

The company’s second-quarter revenue rose 11% to $14.46 billion, with adjusted earnings per share at $2.17—slightly above expectations. AstraZeneca maintained its 2025 forecast and raised its interim dividend by 3%.

The U.S. accounted for more than 40% of AstraZeneca’s total revenue in 2024. The company reaffirmed its ambition to reach $80 billion in annual revenue by 2030, with half expected to come from the U.S.

President Trump has warned of possible tariffs on pharmaceutical imports if companies do not lower drug costs within 12 to 18 months.